HR456 is a non-binding House Resolution that designates May 2025 as Progressive Supranuclear Palsy (PSP) Awareness Month and expresses support for PSP awareness, education, and research. The measure acknowledges PSP as an adult-onset neurodegenerative disorder distinct from Parkinson’s disease, outlines the burden of disease with an estimated 30,000 Americans affected, and notes the variety of symptoms that impact quality of life.
It emphasizes the absence of disease-modifying treatments or a cure and calls for greater awareness to improve diagnosis, care, and support for patients and families. Because this is a resolution, it does not authorize spending or create enforceable duties, but it signals congressional commitment to education and research collaboration in the PSP community.
At a Glance
What It Does
The bill designates May 2025 as Progressive Supranuclear Palsy Awareness Month and expresses support for the designation and its goals.
Who It Affects
Patients with PSP, their families, caregivers, health care professionals, researchers, and PSP advocacy groups are directly impacted by heightened awareness and education efforts.
Why It Matters
Raising awareness can reduce misdiagnosis, shorten time to proper care, and build public support for research and resources for PSP patients and caregivers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
This resolution from the House of Representatives formally designates May 2025 as Progressive Supranuclear Palsy Awareness Month. It is a symbolic, non-binding measure that seeks to elevate public understanding of PSP, a distinct neurodegenerative disorder.
The text notes that about 30,000 Americans live with PSP and describes a range of challenging symptoms—from cognitive and motor issues to speech and swallowing difficulties. The resolution emphasizes that there are no disease-modifying treatments or a cure currently, and it calls for increased awareness, education, and ongoing research to improve diagnosis, care, and eventually find better treatments or a cure.
Importantly, the measure does not appropriate funding or impose new obligations; its primary purpose is awareness and endorsement of the PSP community’s needs. The four operative sections express support for the designation, endorse the goals of the awareness month, support ongoing PSP research, and commend the researchers, families, and organizations dedicated to PSP advocacy across the United States.
The Five Things You Need to Know
The bill designates May 2025 as Progressive Supranuclear Palsy Awareness Month.
The resolution is non-binding and does not authorize spending.
It recognizes PSP as a distinct neurodegenerative disease with an estimated 30,000 affected Americans.
It calls for increased awareness, education, and research to improve care and treatment options.
It commends PSP researchers, volunteers, and affected families nationwide.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Designation of PSP Awareness Month
The resolution designates May 2025 as Progressive Supranuclear Palsy Awareness Month and states the House’s support for this designation. This section establishes the formal recognition without creating any new statutory obligations or funding.
Support for goals of PSP Awareness Month
This section expresses support for the goals and ideals associated with PSP Awareness Month, including public education, early awareness, and community engagement. It reinforces the national scope of the effort but does not mandate actions by specific agencies or organizations.
Support for PSP research
The resolution endorses continued research to improve treatments and pursue a cure for PSP. It signals congressional backing for scientific work and associated clinical knowledge, without prescribing funding or programmatic mandates.
Commendation of PSP community
This section commends researchers, volunteers, organizations, families, and individuals across the country who work to improve the lives of people with PSP. It acknowledges the ecosystem of care, advocacy, and support surrounding PSP patients and their networks.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- PSP patients and their families receive greater visibility and acknowledgment, which can facilitate earlier diagnosis and access to resources.
- Caregivers and patient advocates gain recognition and potential better access to support networks.
- Neurology researchers and clinical trial networks benefit from heightened awareness and potential increases in collaboration.
- Hospitals, clinics, and specialty centers focused on neurodegenerative diseases can leverage awareness momentum to inform patients and communities.
- PSP advocacy organizations and foundations gain a national platform for education and outreach.
Who Bears the Cost
- There are no direct federal spending or enforcement obligations created by this non-binding resolution.
- Organizations that run PSP awareness activities may incur minor, voluntary costs tied to outreach and education efforts.
- Hospitals, clinics, and universities hosting PSP-related events could incur small administrative costs if they participate in awareness activities.
- Local and state health departments may absorb minimal costs if they independently pursue PSP awareness initiatives in alignment with broader public health outreach.
- No new regulatory or reporting burdens are imposed on individuals or entities by the measure.
Key Issues
The Core Tension
The central dilemma is whether a non-binding recognition can meaningfully accelerate diagnosis, care, and research for PSP without accompanying funding or policy tools, balancing symbolic value against the risk of unmet expectations.
As a symbolic measure, the resolution relies on awareness and advocacy rather than new policy tools or funding. A key tension is whether elevated awareness will translate into tangible outcomes for patients—such as earlier diagnosis, better access to care, and accelerated research—without any accompanying resources.
The bill does not authorize spending or create enforceable duties, so implementation depends on voluntary actions by advocates, medical institutions, and researchers, which can vary in scale and effectiveness. Additionally, awareness efforts risk overpromising outcomes in the absence of policy levers or funding to support diagnostic or treatment advances, highlighting a broader question about how symbolic recognitions translate into concrete public health gains.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.